Bionyra Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $165M

  • Investors
  • 7

Bionyra General Information

Description

Developer of biologic therapeutics designed to treat immune-mediated inflammatory diseases. The company develops mono- and multispecific antibody therapies utilizing half-life extension technology to target novel immune pathways, enabling patients to achieve durable disease control with reduced dosing frequency.

Contact Information

Website
www.bionyra.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 7-11 Boulevard Haussmann
  • 75009 Paris
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 7-11 Boulevard Haussmann
  • 75009 Paris
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bionyra Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 22-Jun-2026 $165M Completed Pre-Clinical Trials
1. Seed Round Completed Pre-Clinical Trials
To view Bionyra’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Bionyra Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bionyra Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Apollo Health Ventures Venture Capital Minority
Arkin Capital Asset Manager Minority
Jeito Growth/Expansion Minority
Sanofi Ventures Corporate Venture Capital Minority
Sixty Degree Capital Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Bionyra FAQs

  • When was Bionyra founded?

    Bionyra was founded in 2025.

  • Where is Bionyra headquartered?

    Bionyra is headquartered in Paris, France.

  • What is the size of Bionyra?

    Bionyra has 20 total employees.

  • What industry is Bionyra in?

    Bionyra’s primary industry is Drug Discovery.

  • Is Bionyra a private or public company?

    Bionyra is a Private company.

  • What is Bionyra’s current revenue?

    The current revenue for Bionyra is .

  • How much funding has Bionyra raised over time?

    Bionyra has raised $165M.

  • Who are Bionyra’s investors?

    Apollo Health Ventures, Arkin Capital, Jeito, Sanofi Ventures, and Sixty Degree Capital are 5 of 7 investors who have invested in Bionyra.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process